Glo-BNHL

Clinical research into new treatments for relapsed or refractory B-cell non-Hodgkin lymphoma.

Recruiting

Who can enter

Children with non-Hodgkin lymphoma in whom the disease does not respond sufficiently to treatment (refractory B-NHL), or in whom the disease has recurred (relapsed B-NHL)
Age: up to 18 years of age

Goal

The goal of the Glo-BNHL study is to see how well new treatments work for B-cell non-Hodgkin Lymphomas that have not responded to previous treatment, or have relapsed. We will also look at what the side effects are. In this way, we hope to find new treatments that have fewer side effects or can cure more children.

Background

B-cell non-Hodgkin lymphoma (B-NHL) is a form of lymph node cancer. With the treatments available today, we can cure many patients. Unfortunately, these treatments do not work in all patients. In a small number of patients, the cancer does not go away (refractory B-NHL) or comes back (relapsed B-NHL).

In the Glo-BNHL, we want to investigate several new treatments for children and young adults with relapsed or refractory B-NHL. Two possible treatments are currently available:

Treatment with the drug odronextamab,
Or treatment with the drug loncastuximab tesirine (lonca).

Odronextamab is a drug that can attach to the immune cells, as well as the cancer cells. In this way, the body’s own immune cells are brought close to the cancer cell and thus the immune system can specifically attack the cancer cells.

Odronextamab is given through the central line. For the first 12 weeks, this is given once a week. After 12 weeks, odronextamab is given once every 2 weeks, and after 9 months, odronextamab may be given once every 4 weeks. It may be necessary to give a course of chemotherapy first before treatment with odronextamab.

Lonca is a drug that very specifically seeks out and kills cancer cells. Lonca is given in addition to the normal treatment of three courses of R-ICE chemotherapy (rituximab, ifosfamide, carboplatin and etoposide). On every second day of a course, we administer lonca through the central line. Thus, 3 doses of lonca are given.

With both treatments, additional blood is drawn to study how the drug is processed in the body. Additional testing is also possible. Extra blood is taken for this purpose. For the extra examination, we also use bone marrow, cerebrospinal fluid, fluid from the lungs or abdomen, and/or tumor tissue that was taken in routine care. The additional examination is optional. Permission for this is requested separately.

Odronextamab and lonca are both approved for use in adults.

In order to participate in a study please refer to your/your child’s doctor.
For international patients: please feel welcome to contact our International Patients Office.

Last reviewed

February 24, 2026

Study details
Official title
Glo-BNHL: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Cancer type
Relapsed or refractory B-cell non-Hodgkin Lymphoma
Phase
2/3
Maximum number of patients
- 30-60 patients for the odronextamab treatment, of whom 4 are expected to participate in the Netherlands
- 15-30 patients for the lonca treatment, of whom 4 are expected to participate in the Netherlands
Start date
February 24, 2026
Status
Open
Local principal investigator
Dr. E. Brivio
Sponsor
University of Birmingham
Approval
The study of this new treatment has been reviewed by an accredited medical research ethics committee. This committee has decided that it is justified to ask patients to participate in this study. More information can be found at: CCMO.
Trial registry number
EU Clinical Trials: 2024-510575-38
ClinialTrials.gov: NCT05991388